- Home
- FRD vs RGLS Comparison
FRD vs RGLS Comparison
Compare FRD & RGLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRD
- RGLS
- Stock Information
- Founded
- FRD 1965
- RGLS 2007
- Country
- FRD United States
- RGLS United States
- Employees
- FRD N/A
- RGLS N/A
- Industry
- FRD Steel/Iron Ore
- RGLS Biotechnology: Pharmaceutical Preparations
- Sector
- FRD Industrials
- RGLS Health Care
- Exchange
- FRD Nasdaq
- RGLS Nasdaq
- Market Cap
- FRD 99.3M
- RGLS 102.1M
- IPO Year
- FRD N/A
- RGLS 2012
- Fundamental
- Price
- FRD $14.61
- RGLS $1.43
- Analyst Decision
- FRD
- RGLS Strong Buy
- Analyst Count
- FRD 0
- RGLS 6
- Target Price
- FRD N/A
- RGLS $10.33
- AVG Volume (30 Days)
- FRD 10.3K
- RGLS 503.4K
- Earning Date
- FRD 11-12-2024
- RGLS 11-07-2024
- Dividend Yield
- FRD 1.11%
- RGLS N/A
- EPS Growth
- FRD N/A
- RGLS N/A
- EPS
- FRD 1.14
- RGLS N/A
- Revenue
- FRD $469,515,000.00
- RGLS N/A
- Revenue This Year
- FRD N/A
- RGLS N/A
- Revenue Next Year
- FRD N/A
- RGLS N/A
- P/E Ratio
- FRD $12.74
- RGLS N/A
- Revenue Growth
- FRD N/A
- RGLS N/A
- 52 Week Low
- FRD $11.15
- RGLS $1.08
- 52 Week High
- FRD $19.52
- RGLS $3.79
- Technical
- Relative Strength Index (RSI)
- FRD 49.69
- RGLS 44.08
- Support Level
- FRD $13.85
- RGLS $1.38
- Resistance Level
- FRD $14.72
- RGLS $1.65
- Average True Range (ATR)
- FRD 0.61
- RGLS 0.11
- MACD
- FRD 0.06
- RGLS 0.00
- Stochastic Oscillator
- FRD 35.35
- RGLS 16.67
About FRD Friedman Industries Inc.
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.
About RGLS Regulus Therapeutics Inc.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.